Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	3	JAN 25	Annual Reload of MEDLINE database
NEWS	4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS	9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	11	APR 02	DWPI: New display format ALLSTR available
NEWS	12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	14	APR 07	CA/CAplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS	15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS	16	APR 07	MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:52:16 ON 08 APR 2010

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 10:52:33 ON 08 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 APR 2010 HIGHEST RN 1217434-06-4
DICTIONARY FILE UPDATES: 7 APR 2010 HIGHEST RN 1217434-06-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10599121_genus.str



chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
7-11 7-12 8-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-13 11-17 12-18 12-22 13-14
14-15 15-16 16-17 18-19 19-20 20-21 21-22
exact/norm bonds :
5-7 6-9 7-8 8-9 8-10
exact bonds :

7-11 7-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-13 11-17 12-18 12-22 13-14 14-15 15-16
16-17 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss
SAMPLE SEARCH INITIATED 10:52:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   274 TO ITERATE

100.0% PROCESSED   274 ITERATIONS   42 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 4487 TO   6473
PROJECTED ANSWERS: 452 TO   1228

L2   42 SEA SSS SAM L1

=> d l2 1

L2   ANSWER 1 OF 42 REGISTRY COPYRIGHT 2010 ACS on STN
RN   1201694-96-3 REGISTRY
ED   Entered STN: 08 Jan 2010
CN   2H-Indol-2-one, 5-bromo-3,3-bis[4-[4-[4-[[5-bromo-3,3-bis(4-chlorophenyl)-

2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]benzoyl]phenoxy]phenyl]-1,3-dihydro-
(CA INDEX NAME)

MF C88 H54 Br3 Cl4 N3 O7

SR CA

LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

Uploading C:\Program Files\Stnexp\Queries\10599121_NEW_genus.str



chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
7-11 7-12 8-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-13 11-17 12-18 12-22 13-14
14-15 15-16 16-17 18-19 19-20 20-21 21-22
exact/norm bonds :
6-9 8-9 8-10
exact bonds :
5-7 7-8 7-11 7-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-13 11-17 12-18 12-22 13-14 14-15 15-16
16-17 18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 11 : 12 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l3 sss
SAMPLE SEARCH INITIATED 10:54:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       86 TO ITERATE

100.0% PROCESSED       86 ITERATIONS                              40 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1164 TO     2276
PROJECTED ANSWERS:             421 TO     1179

L4           40 SEA SSS SAM L3

=> d l4

L4   ANSWER 1 OF 40  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   1201694-96-3  REGISTRY
ED   Entered STN:  08 Jan 2010
CN   2H-Indol-2-one, 5-bromo-3,3-bis[4-[4-[4-[[5-bromo-3,3-bis(4-chlorophenyl)-
     2,3-dihydro-2-oxo-1H-indol-1-yl]methyl]benzoyl]phenoxy]phenyl]-1,3-dihydro-
       (CA INDEX NAME)
MF   C88 H54 Br3 Cl4 N3 O7
SR   CA
LC   STN Files:   CA, CAPLUS
```

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s l3 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:54:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1616 TO ITERATE

100.0% PROCESSED     1616 ITERATIONS                              592 ANSWERS
SEARCH TIME: 00.00.01

L5          592 SEA SSS FUL L3

=> file caplus
```

```
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     196.72     196.94

FILE 'CAPLUS' ENTERED AT 10:54:34 ON 08 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Apr 2010 VOL 152 ISS 15
FILE LAST UPDATED: 7 Apr 2010 (20100407/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l5
L6         394 L5

=> s (cancer or tumor or neoplasm or tumour)
        450173 CANCER
         66058 CANCERS
        466420 CANCER
                  (CANCER OR CANCERS)
        539211 TUMOR
        194072 TUMORS
        598245 TUMOR
                  (TUMOR OR TUMORS)
          4791 TUMOUR
          1810 TUMOURS
          6484 TUMOUR
                  (TUMOUR OR TUMOURS)
        598684 TUMOR
                  (TUMOR OR TUMOUR)
        589261 NEOPLASM
         38742 NEOPLASMS
        606639 NEOPLASM
                  (NEOPLASM OR NEOPLASMS)
          4791 TUMOUR
          1810 TUMOURS
          6484 TUMOUR
                  (TUMOUR OR TUMOURS)
        539211 TUMOR
```

```
        194072 TUMORS
        598245 TUMOR
                  (TUMOR OR TUMORS)
        598684 TUMOUR
                  (TUMOUR OR TUMOR)
L7      996285 (CANCER OR TUMOR OR NEOPLASM OR TUMOUR)

=> s l6 and l7
L8          12 L6 AND L7

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9          12 DUP REM L8 (0 DUPLICATES REMOVED)

=> d l9 1-12 ibib abs hitstr

L9   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:        2008:1299768  CAPLUS
DOCUMENT NUMBER:         149:513691
TITLE:                   Preparation of 3-(4-hydroxyphenyl)-indolin-2-ones for
                         the treatment of cancer
INVENTOR(S):             Christensen, Mette Knak; Bjoerkling, Fredrik
PATENT ASSIGNEE(S):      Topotarget A/S, Den.
SOURCE:                  PCT Int. Appl., 123pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2008129075        A1    20081030    WO 2008-EP54990        20080424
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
     AU 2008240599        A1    20081030    AU 2008-240599         20080424
     CA 2684552           A1    20081030    CA 2008-2684552        20080424
     EP 2139856           A1    20100106    EP 2008-749700         20080424
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
             SK, TR
PRIORITY APPLN. INFO.:                       US 2007-913625P     P  20070424
                                             WO 2008-EP54990     W  20080424
OTHER SOURCE(S):         MARPAT 149:513691
GI



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

AB   Title compds. I [r = 0 or 1; X = -CH2-, -O-, -S-, etc.; Z =
```

(un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted alkenyl, etc.; V1-V4 = carbon atom, non-quaternary nitrogen atom, oxygen atom, etc.; R1-R4, when attached to a carbon atom, are independently H, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; R1-R4, when attached to a nitrogen atom, are independently H, (un)substituted alkyl, hydroxy, etc.; R1 and R2 together with the carbon atoms to which they attached may form a ring; with the proviso that at least one of R1-R4 is not H] and pharmaceutically acceptable salts and prodrugs thereof were prepared For example, compound II was prepared by following general procedure: treatment of 3-substituted-3-hydroxy-indolin-2-one with phenol (5.0 equiv) and p-TsOH (7.5 equiv) in dichloroethane at 90° for 2-4 h. In cell proliferation assay (WST assay) using MCF-7, the IC50 of compound II was 3.4 nM.

IT 1073261-12-7P 1073261-13-8P 1073261-20-7P
1073261-21-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-hydroxyphenyl)-indolin-2-ones for treatment of cancer)

RN 1073261-12-7 CAPLUS
CN 2H-Indol-2-one, 3-(3,4-difluorophenyl)-6,7-difluoro-1,3-dihydro-3-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 1073261-13-8 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-3-(3-fluoro-4-methylphenyl)-1,3-dihydro-3-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 1073261-20-7 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxy-3-methylphenyl)-3-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 1073261-21-8 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxy-2-methylphenyl)-3-(4-hydroxyphenyl)- (CA INDEX NAME)



IT 1073262-14-2P 1073262-15-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(4-hydroxyphenyl)-indolin-2-ones for treatment of cancer)

RN 1073262-14-2 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxy-3-methylphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



RN 1073262-15-3 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxy-2-methylphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:733160 CAPLUS
DOCUMENT NUMBER: 149:53867
TITLE: Preparation of prodrugs of 3,3-diphenyl-1,3-dihydroindol-2-one for the treatment of cancer
INVENTOR(S): Christensen, Mette Knak; Bjoerkling, Fredrik; Ikaunieks, Martins; Zaichenko, Andrei; Gailite, Vija; Loza, Einars; Kalvinsh, Ivars; Madre, Marina
PATENT ASSIGNEE(S): Topotarget A/S, Den.
SOURCE: PCT Int. Appl., 85pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008071387	A1	20080619	WO 2007-EP10805	20071211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2102158	A1	20090923	EP 2007-866234	20071211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
US 20100029646	A1	20100204	US 2009-518545	20091005
PRIORITY APPLN. INFO.:			US 2006-869428P P	20061211
			WO 2007-EP10805 W	20071211

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 149:53867; MARPAT 149:53867
GI



I

AB Title compds. [I; X1, X2 = prodrug group; Rn = prodrug group, H, OH, (substituted) alkyl, alkoxy, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl, etc.; V1-V4 = C, N, O, S, bond; R1-R4 = H, OH, NO2, halo, (substituted) alkyl, alkoxy, alkenyl, alkenyloxy, alkoxycarbonyl, alkylthio, aryl, heterocyclyl, etc.; R1R2 = atoms to form a ring; with provisos], were prepared as anticancer drugs (no data). Thus, 6,7-difluoro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)-1,3-dihydroindol-2-one and Boc-Ala-OH were coupled using EDC and DMAP in CH2Cl2 followed by deprotection with HCl in Et2O to give (2S)-4-(6,7-difluoro-3-(4-methoxyphenyl)-2-oxoindolin-3-yl)phenyl 2-aminopropanoate hydrochloride.

IT 1033126-98-5P 1033126-99-6P 1033127-01-3P
1033127-02-4P 1033127-03-5P 1033127-04-6P
1033127-06-8P 1033127-08-0P 1033127-09-1P
1033127-11-5P 1033127-12-6P 1033127-15-9P
1033127-16-0P 1033127-17-1P 1033127-18-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of prodrugs of di-Ph oxindoles for the treatment of cancer)

RN 1033126-98-5 CAPLUS

CN L-Alanine, 4-[6,7-difluoro-2,3-dihydro-3-(4-methoxyphenyl)-2-oxo-1H-indol-3-yl]phenyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033126-99-6 CAPLUS

CN L-Alanine, 1,1'-[(6,7-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)di-4,1-

phenylene] ester, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1033127-01-3 CAPLUS
CN Glycine, 1,1'-[(6,7-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene] ester, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 1033127-00-2
CMF C24 H19 F2 N3 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1033127-02-4 CAPLUS
CN L-Valine, N-methyl-, 1,1'-[(6,7-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene] ester, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1033127-03-5 CAPLUS
CN Glycine, N,N-dimethyl-, 1,1'-[(6,7-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene] ester (CA INDEX NAME)



RN 1033127-04-6 CAPLUS
CN L-Phenylalanine, 4-[6,7-difluoro-2,3-dihydro-3-(4-methoxyphenyl)-2-oxo-1H-indol-3-yl]phenyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033127-06-8 CAPLUS
CN Carbonic acid, 4-[3-(4-chlorophenyl)-6,7-difluoro-2,3-dihydro-2-oxo-1H-indol-3-yl]phenyl [2-(4-morpholinyl)ethoxy]methyl ester (CA INDEX NAME)



RN 1033127-08-0 CAPLUS
CN Carbonic acid, C,C'-[(6-fluoro-1,2-dihydro-7-methyl-2-oxo-3H-indol-3-ylidene)bis(4,1-phenyleneoxymethylene)] C,C'-bis[2-(4-morpholinyl)ethyl] ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1033127-09-1 CAPLUS
CN Phosphonic acid, P-methyl-, 4-[3-(4-chlorophenyl)-2,3-dihydro-6,7-dimethyl-2-oxo-1H-indol-3-yl]phenyl methyl ester (CA INDEX NAME)



RN 1033127-11-5 CAPLUS
CN 4-Morpholinepropanoic acid, 4-[6,7-difluoro-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)



RN 1033127-12-6 CAPLUS
CN 1-Piperazinepropanoic acid, 4-methyl-, 4-[6,7-difluoro-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)



RN 1033127-15-9 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3,3-bis[4-[[(phenylamino)carbonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1033127-16-0 CAPLUS
CN Carbamic acid, N,N-dimethyl-, 4-[6,7-difluoro-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)



RN 1033127-17-1 CAPLUS
CN Carbamic acid, N,N-dimethyl-, 4-[6-fluoro-3-(4-fluorophenyl)-2,3-dihydro-7-methyl-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)



RN 1033127-18-2 CAPLUS
CN 2-Propenoic acid, 4-[6-fluoro-3-(4-fluorophenyl)-2,3-dihydro-7-methyl-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)



IT 1033127-26-2P 1033127-27-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of prodrugs of di-Ph oxindoles for the treatment of cancer)

RN 1033127-26-2 CAPLUS
CN Carbonic acid, [4-[2,3-dihydro-3-(4-methoxyphenyl)-2-oxo-1H-indol-3-yl]phenoxy]methyl 1-methylethyl ester (CA INDEX NAME)



RN 1033127-27-3 CAPLUS
CN Acetic acid, 2-[4-[2,3-dihydro-3-(4-methoxyphenyl)-2-oxo-1H-indol-3-yl]phenoxy]-, phenylmethyl ester (CA INDEX NAME)



IT 125-13-3 867154-86-7 867154-99-2
867155-00-8 1033127-28-4 1033127-30-8
1033127-31-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of prodrugs of di-Ph oxindoles for the treatment of cancer)
RN 125-13-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-86-7 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-99-2 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxyphenyl)-3-(4-methylphenyl)- (CA INDEX NAME)



RN 867155-00-8 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



RN 1033127-28-4 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-3-(4-fluorophenyl)-1,3-dihydro-3-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 1033127-30-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



RN 1033127-31-9 CAPLUS
CN 2H-Indol-2-one, 6-fluoro-3-(4-fluorophenyl)-1,3-dihydro-3-(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



IT 1033127-19-3P 1033127-20-6P 1033127-21-7P
1033127-22-8P 1033127-23-9P 1033127-24-0P
1033127-25-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of prodrugs of di-Ph oxindoles for the treatment of cancer)

RN 1033127-19-3 CAPLUS
CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[6,7-difluoro-2,3-dihydro-3-(4-methoxyphenyl)-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1033127-20-6 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[6,7-difluoro-2,3-dihydro-3-(4-methoxyphenyl)-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1033127-21-7 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-[6,7-difluoro-2,3-dihydro-3-(4-methylphenyl)-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1033127-22-8 CAPLUS
CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-,
1,1'-[(6,7-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene]
ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1033127-23-9 CAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-,
1,1'-[(6,7-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene]
ester (CA INDEX NAME)



RN 1033127-24-0 CAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-, 1,1'-[(6,7-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1033127-25-1 CAPLUS
CN 2-Propenoic acid, 4-[6,7-difluoro-3-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]phenyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:221461 CAPLUS
DOCUMENT NUMBER: 148:292088
TITLE: Pharmaceutical oral formulations of cannabinoids for decreasing potential abuse and toxicity
INVENTOR(S): Babul, Najib
PATENT ASSIGNEE(S): Theraquest Biosciences, LLC, USA
SOURCE: PCT Int. Appl., 190pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021394	A2	20080221	WO 2007-US18062	20070815
WO 2008021394	A3	20081231		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:		
US 2006-837606P	P	20060815
US 2006-837607P	P	20060815
US 2006-842359P	P	20060906
US 2006-849006P	P	20061004

AB The present invention is directed to pharmaceutical compns. of cannabinoid agonists and the use thereof for preventing or minimizing the risk of cannabinoid agonist abuse and/or cannabinoid agonist toxicity from either intentional or unintentional tampering. The present invention is also directed at a method of preventing or minimizing the risk of cannabinoid agonist abuse and/or cannabinoid agonist toxicity from either intentional or unintentional tampering. Thus, a mixture containing 700 g rimonabant HCl (aversive agent), 5 g Methocel E5P, 200 g ethanol and 200 g water was coated onto 700 g of sugar spheres in fluidized-bed and the cores obtained were then coated with a sequestering overcoating composition containing 140 g Eudragit RS30D, 14 g tri-Et citrate and 1260 g ethanol up to a 20% to 60% weight gain. A tablet formulation comprising an immediate release cannabinoid agonist Δ9-tetrahydrocannabinol (THC) with a suitable amount of substantially non-releasable aversive agent was prepared by granulation of a mixture containing THC 25 mg, polyvinylpyrrolidone 7.5 mg, lactose 30 mg, Alc. SD3A-2 proof 3 mL stearic acid 5 mg, talc 705 mg, corn starch 20 mg, and rimonabant HCl spheres suitable amount and compression.

IT 125-13-3, Oxyphenisatine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of oral compns. of cannabinoids for decreasing potential abuse and toxicity)

RN 125-13-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L9 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:478005 CAPLUS
DOCUMENT NUMBER: 147:95492
TITLE: Syntheses and antiproliferative evaluation of oxyphenisatin derivatives
AUTHOR(S): Uddin, Muhammed K.; Reignier, Serge G.; Coulter, Tom; Montalbetti, Christian; Granaes, Charlotta; Butcher, Steven; Krog-Jensen, Christian; Felding, Jakob
CORPORATE SOURCE: Evotec(UK) Ltd., Abingdon, Oxon, OX14 4RX, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 2854-2857
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:95492
GI



I



II

AB Syntheses and structure-antiproliferative relationship for oxyphenisatin analogs are described. The cell proliferation data showed that the presence of substituents (especially F, Cl, Me, CF3, and OMe) in the 6- and 7-position of oxyphenisatin markedly enhanced the potency in the MDA-468 cell line without affecting the MDA-231 cell line. The best compds. I and II showed low nanomolar antiproliferative activity towards the MDA-468 cell line and a 1000-fold selectivity over the MDA-231 cell line.

IT 867154-95-8P
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxyphenisatin derivs. starting from anilines using

substituted isatins as key intermediates and double Friedel-Crafts reaction as key step, and their anticancer activity and SAR)

RN 867154-95-8 CAPLUS

CN 2H-Indol-2-one, 7-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6-methyl- (CA INDEX NAME)



IT 20206-13-7P 20206-14-8P 20518-58-5P
47414-01-7P 47465-96-3P 56632-39-4P
97573-55-2P 426251-98-1P 859068-47-6P
861070-76-0P 867154-61-8P 867154-62-9P
867154-67-4P 867154-68-5P 867154-69-6P
867154-72-1P 867154-76-5P 867154-77-6P
867154-78-7P 867154-79-8P 867154-80-1P
867154-81-2P 867154-83-4P 867154-84-5P
867154-85-6P 867154-86-7P 867154-87-8P
867154-88-9P 867154-89-0P 867154-90-3P
867154-91-4P 942492-99-1P 942493-00-7P
942493-01-8P 942493-02-9P 942493-03-0P
942493-04-1P 942493-05-2P 942493-06-3P
942493-07-4P 942493-08-5P 942493-09-6P
942493-10-9P 942493-11-0P 942493-12-1P
942493-13-2P 942493-14-3P 942493-15-4P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of oxyphenisatin derivs. starting from anilines using substituted isatins as key intermediates and double Friedel-Crafts reaction as key step, and their anticancer activity and SAR)

RN 20206-13-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6-methoxy- (CA INDEX NAME)



RN 20206-14-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6,7-dimethyl- (CA INDEX NAME)



RN 20518-58-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-methoxy- (CA INDEX NAME)



RN 47414-01-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-methyl- (CA INDEX NAME)



RN 47465-96-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5,7-dimethyl- (CA INDEX NAME)



RN 56632-39-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 97573-55-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6-methyl- (CA INDEX NAME)



RN 426251-98-1 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 859068-47-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-iodo- (CA INDEX NAME)



RN 861070-76-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-61-8 CAPLUS
CN 1H-Indole-7-carboxylic acid, 2,3-dihydro-3,3-bis(4-hydroxyphenyl)-2-oxo- (CA INDEX NAME)



RN 867154-62-9 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-67-4 CAPLUS
CN 2H-Indol-2-one, 6-bromo-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-68-5 CAPLUS
CN 2H-Indol-2-one, 7-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-69-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methoxy- (CA INDEX NAME)



RN 867154-72-1 CAPLUS
CN 2H-Indol-2-one, 6-chloro-3,3-bis(4-fluorophenyl)-1,3-dihydro-7-methyl- (CA INDEX NAME)



RN 867154-76-5 CAPLUS
CN 2H-Indol-2-one, 7-bromo-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-77-6 CAPLUS
CN Methanesulfonamide, N,N'-[(6-chloro-1,2-dihydro-7-methyl-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene]bis- (CA INDEX NAME)



RN 867154-78-7 CAPLUS
CN 2H-Indol-2-one, 7-ethyl-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-79-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-iodo- (CA INDEX NAME)



RN 867154-80-1 CAPLUS
CN 2H-Indol-2-one, 7-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-81-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-(trifluoromethyl)- (CA INDEX NAME)



RN 867154-83-4 CAPLUS
CN 2H-Indol-2-one, 5,7-difluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-84-5 CAPLUS
CN 2H-Indol-2-one, 6-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-85-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6-methoxy-7-methyl- (CA INDEX NAME)



RN 867154-86-7 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-87-8 CAPLUS
CN 2H-Indol-2-one, 6-chloro-7-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-88-9 CAPLUS
CN 1H-Indole-7-carbonitrile, 2,3-dihydro-3,3-bis(4-hydroxyphenyl)-2-oxo- (CA INDEX NAME)



RN 867154-89-0 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-90-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-methoxy-7-methyl- (CA INDEX NAME)



RN 867154-91-4 CAPLUS
CN 2H-Indol-2-one, 6-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 942492-99-1 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-7-methyl-3,3-diphenyl- (CA INDEX NAME)



RN 942493-00-7 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-3,3-bis(4-methoxyphenyl)-7-methyl- (CA INDEX NAME)



RN 942493-01-8 CAPLUS
CN 2H-Indol-2-one, 3,3-bis(4-aminophenyl)-6-chloro-1,3-dihydro-7-methyl- (CA INDEX NAME)



RN 942493-02-9 CAPLUS
CN 2H-Indol-2-one, 6-chloro-3,3-bis[4-(dimethylamino)phenyl]-1,3-dihydro-7-methyl- (CA INDEX NAME)



RN 942493-03-0 CAPLUS
CN Acetamide, N,N'-[(6-chloro-1,2-dihydro-7-methyl-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene]bis- (CA INDEX NAME)



RN 942493-04-1 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-3,3-bis(2-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 942493-05-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-phenyl- (CA INDEX NAME)



RN 942493-06-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-(2-thienyl)- (CA INDEX NAME)



RN 942493-07-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-(4-pyridinyl)- (CA INDEX NAME)



RN 942493-08-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-3,3-bis(4-hydroxyphenyl)-2-oxo- (CA INDEX NAME)



RN 942493-09-6 CAPLUS
CN 2H-Indol-2-one, 7-ethynyl-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 942493-10-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-(1-methylethyl)- (CA INDEX NAME)



RN 942493-11-0 CAPLUS
CN 2H-Indol-2-one, 7-(1,1-dimethylethyl)-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 942493-12-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-phenyl- (CA INDEX NAME)



RN 942493-13-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-(2-thienyl)- (CA INDEX NAME)



RN 942493-14-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-(4-pyridinyl)- (CA INDEX NAME)



RN 942493-15-4 CAPLUS
CN 1H-Indole-7-carboxamide, 2,3-dihydro-3,3-bis(4-hydroxyphenyl)-N,N-dimethyl-2-oxo- (CA INDEX NAME)



IT 942493-18-7P 942493-19-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxyphenisatin derivs. starting from anilines using substituted isatins as key intermediates and double Friedel-Crafts reaction as key step, and their anticancer activity and SAR)
RN 942493-18-7 CAPLUS
CN 2H-Indol-2-one, 7-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)



RN 942493-19-8 CAPLUS

CN 2H-Indol-2-one, 7-chloro-6-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



IT 94880-97-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of oxyphenisatin derivs. starting from anilines using substituted isatins as key intermediates and double Friedel-Crafts reaction as key step, and their anticancer activity and SAR)
RN 94880-97-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:795553 CAPLUS
DOCUMENT NUMBER: 145:230533
TITLE: Preparation of xanthene and tris phenyl compounds as tumor necrosis factor inhibitors
INVENTOR(S): Greene, Mark I.; Murali, Ramachandran; Cheng, Xin; Ottenbrite, Raphael; Xiao, Yingxin
PATENT ASSIGNEE(S): Ception Therapeutics, Inc., USA; Trustees of the University of Pennsylvania
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2006083970	A2	20060810	WO 2006-US3574		20060131
WO 2006083970	A3	20061123			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2006210778	A2	20060810	AU 2006-210778		20060131
AU 2006210778	A1	20060810			
CA 2596355	A1	20060810	CA 2006-2596355		20060131
EP 1845970	A2	20071024	EP 2006-734168		20060131
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
JP 2008528634	T	20080731	JP 2007-553377		20060131
US 20090221527	A1	20090903	US 2008-815134		20081204
PRIORITY APPLN. INFO.:			US 2005-648973P	P	20050131
			WO 2006-US3574	W	20060131

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 145:230533; MARPAT 145:230533
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention is directed to compds. that are allosteric inhibitors of tumor necrosis factor receptor I, compns. comprising such compds., and methods of using such compds. and compns. thereof in the treatment of TNF-α mediated conditions. Specifically the invention is directed towards compds. represented by formula I, II, or III wherein R1-R12 = H, alkyl, OH, alkoxy, halo, NO2, CN, borono, aryl, aryloxy, etc.; X is absent or = O, NR28, or S; and R28 = H, alkyl, or aryl. These small mol. compds. bind to an allosteric site on TNF-R1, thus inhibiting binding of TNF-α to TNF-R1 and reducing activity of the TNF-α/TNF-R1 signaling pathway. Synthesis of some of the compds. is exemplified. For example, IV was prepared by reacting Me bromoacetate and 1,1,1-tris(4-hydroxyphenyl)ethane. In a TNF-α mediated cytolysis assay, IV (25-100 μM) caused 14.8-36.7% inhibition.

IT 115-33-3, 3,3-Bis[4-(acetyloxy)phenyl]-1,3-dihydro-2H-indol-2-one
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug candidate; preparation of xanthene and tris Ph compds. as tumor necrosis factor inhibitors for treating autoimmune or inflammatory conditions)

RN 115-33-3 CAPLUS
CN 2H-Indol-2-one, 3,3-bis[4-(acetyloxy)phenyl]-1,3-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L9 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:796143 CAPLUS
DOCUMENT NUMBER: 145:230413
TITLE: Preparation of xanthene and tris phenyl compounds as tumor necrosis factor inhibitors
INVENTOR(S): Xiao, Yingxin; Ottenbrite, Raphael
PATENT ASSIGNEE(S): Ception Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 78pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006083869	A2	20060810	WO 2006-US3403	20060131
WO 2006083869	A3	20070125		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-648973P P 20050131
OTHER SOURCE(S): CASREACT 145:230413; MARPAT 145:230413
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention is directed to compds. that are allosteric inhibitors of tumor necrosis factor receptor I, compns. comprising such compds., and methods of using such compds. and compns. thereof in the treatment of TNF-α mediated conditions. Specifically the invention is directed towards compds. represented by formula I, II, or III wherein R1-R12 = H, alkyl, OH, alkoxy, halo, NO2, CN, borono, aryl, aryloxy, etc.; X is absent or = O, NR28, or S; R28 = H, alkyl, or aryl;

q-x = 0-3. These small mol. compds. bind to an allosteric site on TNF-R1, thus inhibiting binding of TNF-α to TNF-R1 and reducing activity of the TNF-α/TNF-R1 signaling pathway. Synthesis of some of the compds. is exemplified. For example, IV was prepared by reacting Me bromoacetate and 1,1,1-tris(4-hydroxyphenyl)ethane. In a TNF-α mediated cytolysis assay, IV (25-100 μM) caused 14.8-36.7% inhibition.

IT 115-33-3, 3,3-Bis[4-(acetyloxy)phenyl]-1,3-dihydro-2H-indol-2-one
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug candidate; preparation of xanthene and tris Ph compds. as tumor necrosis factor inhibitors for treating autoimmune or inflammatory conditions)

RN 115-33-3 CAPLUS
CN 2H-Indol-2-one, 3,3-bis[4-(acetyloxy)phenyl]-1,3-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L9 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1123755 CAPLUS
DOCUMENT NUMBER: 143:405798
TITLE: Preparation of 3,3-diphenyl-indol-2-one derivatives as anticancer agents
INVENTOR(S): Felding, Jakob; Pedersen, Hans Christian; Krog-Jensen, Christian; Praestegaard, Morten; Butcher, Steven Peter; Linde, Viggo; Coulter, Thomas Stephen; Montalbetti, Christian; Uddin, Mohammed; Reignier, Serge
PATENT ASSIGNEE(S): Biolmage A/S, Den.
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097107	A2	20051020	WO 2005-DK244	20050408
WO 2005097107	A3	20060330		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, SI, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005230232	A1	20051020	AU 2005-230232	20050408
CA 2562399	A1	20051020	CA 2005-2562399	20050408
EP 1734951	A2	20061227	EP 2005-715161	20050408
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1953747	A	20070425	CN 2005-80010250	20050408
BR 2005009745	A	20070925	BR 2005-9745	20050408
JP 2007532496	T	20071115	JP 2007-506660	20050408
MX 2006010822	A	20061120	MX 2006-10822	20060921
ZA 2006008044	A	20080130	ZA 2006-8044	20060927
IN 2006KN03070	A	20070608	IN 2006-KN3070	20061023
NO 2006005034	A	20061102	NO 2006-5034	20061102
KR 2006130781	A	20061219	KR 2006-723439	20061108
US 20070299102	A1	20071227	US 2007-599121	20070601

PRIORITY APPLN. INFO.:

DK 2004-576	A	20040408
DK 2004-693	A	20040501
DK 2004-1153	A	20040727
DK 2004-1216	A	20040811
WO 2005-DK244	W	20050408

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:405798; MARPAT 143:405798

GI



I

AB Title compds. represented by the formula I [R1 = H, halo, alkyl, etc.; R2 = H, halo, (un)substituted aryl, etc.; R3 = H, (un)substituted alkoxy, halo, etc.; Z = CH or N; X1, X2 = independently halo, amino, aminosulfonylalkyl, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as anticancer agents. For example, 6-chloro-3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-indol-2-one (II) was provided in a multi-step synthesis starting from 2-methyl-3-chloroaniline. I showed inhibition of proliferation of MDA-468 human breast cancer cells at lower concns., and II was tested in protein synthesis, translation control, PC3M human prostate cancer cell and etc. Thus, I and their pharmaceutical compns. are useful for the treatment of cancers in which inhibition of protein synthesis and/or inhibition of activation of the mTOR pathway is an effective method for reducing cell growth, such as human breast cancer and prostate cancer.

IT 20206-13-7P, 3,3-Bis(4-hydroxyphenyl)-6-methoxy-1,3-dihydroindol-2-one 20206-14-8P, 3,3-Bis(4-hydroxyphenyl)-6,7-dimethyl-1,3-

dihydroindol-2-one 20518-58-5P,
3,3-Bis(4-hydroxyphenyl)-5-methoxy-1,3-dihydroindol-2-one
47414-01-7P, 3,3-Bis(4-hydroxyphenyl)-5-methyl-1,3-dihydroindol-2-
one 47465-96-3P, 3,3-Bis(4-hydroxyphenyl)-5,7-dimethyl-1,3-
dihydroindol-2-one 97573-55-2P,
3,3-Bis(4-hydroxyphenyl)-6-methyl-1,3-dihydroindol-2-one
352691-99-7P 426251-98-1P 859068-47-6P,
3,3-Bis(4-hydroxyphenyl)-5-iodo-1,3-dihydroindol-2-one
861070-76-0P 867154-57-2P 867154-58-3P
867154-59-4P 867154-60-7P,
3,3-Bis(4-hydroxyphenyl)-5-trifluoromethoxy-1,3-dihydroindol-2-one
867154-61-8P, 3,3-Bis(4-hydroxyphenyl)-2-oxo-2,3-dihydro-1H-indole-
7-carboxylic acid 867154-62-9P 867154-63-0P,
3,3-Bis(4-hydroxyphenyl)-5-nitro-1,3-dihydroindol-2-one
867154-64-1P 867154-65-2P 867154-66-3P
867154-67-4P 867154-68-5P,
3,3-Bis(4-hydroxyphenyl)-7-fluoro-1,3-dihydroindol-2-one
867154-69-6P, 3,3-Bis(4-hydroxyphenyl)-7-methoxy-1,3-dihydroindol-
2-one 867154-70-9P 867154-72-1P
867154-73-2P, 3,3-Bis(4-hydroxyphenyl)-7-[(morpholin-4-
yl)carbonyl]-1,3-dihydroindol-2-one 867154-76-5P
867154-77-6P 867154-78-7P 867154-79-8P,
3,3-Bis(4-hydroxyphenyl)-7-iodo-1,3-dihydroindol-2-one
867154-80-1P, 3,3-Bis(4-hydroxyphenyl)-7-chloro-1,3-dihydroindol-2-
one 867154-81-2P, 3,3-Bis(4-hydroxyphenyl)-7-trifluoromethyl-
1,3-dihydroindol-2-one 867154-82-3P, Acetic acid
4-[3-(4-acetoxyphenyl)-6-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-
yl]phenyl ester 867154-83-4P 867154-84-5P
867154-85-6P, 3,3-Bis(4-hydroxyphenyl)-6-methoxy-7-methyl-1,3-
dihydroindol-2-one 867154-86-7P 867154-87-8P
867154-88-9P, 3,3-Bis(4-hydroxyphenyl)-2-oxo-2,3-dihydro-1H-indole-
7-carbonitrile 867154-89-0P 867154-90-3P,
3,3-Bis(4-hydroxyphenyl)-5-methoxy-7-methyl-1,3-dihydroindol-2-one
867154-91-4P 867154-93-6P 867154-94-7P,
5-[[3,3-Bis(4-hydroxyphenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-6-
yl]oxy]pentanoic acid 867154-95-8P 867154-96-9P,
5-Hydroxy-3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydroindol-2-one
867154-97-0P 867154-98-1P 867154-99-2P
867155-00-8P 867155-01-9P 867155-02-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 3,3-di-Ph-indol-2-one derivs. as anticancer agents)

RN 20206-13-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6-methoxy- (CA INDEX
NAME)



RN 20206-14-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6,7-dimethyl- (CA

INDEX NAME)



RN 20518-58-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-methoxy- (CA INDEX NAME)



RN 47414-01-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-methyl- (CA INDEX NAME)



RN 47465-96-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5,7-dimethyl- (CA INDEX NAME)



RN 97573-55-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6-methyl- (CA INDEX NAME)



RN 352691-99-7 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 426251-98-1 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 859068-47-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-iodo- (CA INDEX NAME)



RN 861070-76-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-57-2 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-7-methyl-3,3-bis(4-methylphenyl)- (CA INDEX NAME)



RN 867154-58-3 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl-5-nitro- (CA INDEX NAME)



RN 867154-59-4 CAPLUS
CN 2H-Indol-2-one, 5-amino-6-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-60-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 867154-61-8 CAPLUS
CN 1H-Indole-7-carboxylic acid, 2,3-dihydro-3,3-bis(4-hydroxyphenyl)-2-oxo- (CA INDEX NAME)



RN 867154-62-9 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-63-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-nitro- (CA INDEX NAME)



RN 867154-64-1 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-65-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-66-3 CAPLUS
CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-67-4 CAPLUS
CN 2H-Indol-2-one, 6-bromo-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-68-5 CAPLUS
CN 2H-Indol-2-one, 7-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-69-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methoxy- (CA INDEX NAME)



RN 867154-70-9 CAPLUS
CN 2H-Indol-2-one, 4,7-dichloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-72-1 CAPLUS
CN 2H-Indol-2-one, 6-chloro-3,3-bis(4-fluorophenyl)-1,3-dihydro-7-methyl- (CA INDEX NAME)



RN 867154-73-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-(4-morpholinylcarbonyl)- (CA INDEX NAME)



RN 867154-76-5 CAPLUS
CN 2H-Indol-2-one, 7-bromo-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-77-6 CAPLUS
CN Methanesulfonamide, N,N'-[(6-chloro-1,2-dihydro-7-methyl-2-oxo-3H-indol-3-ylidene)di-4,1-phenylene]bis- (CA INDEX NAME)



RN 867154-78-7 CAPLUS
CN 2H-Indol-2-one, 7-ethyl-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-79-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-iodo- (CA INDEX NAME)



RN 867154-80-1 CAPLUS
CN 2H-Indol-2-one, 7-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-81-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-(trifluoromethyl)- (CA INDEX NAME)



RN 867154-82-3 CAPLUS
CN 2H-Indol-2-one, 3,3-bis[4-(acetyloxy)phenyl]-6-chloro-1,3-dihydro-7-methyl- (CA INDEX NAME)



RN 867154-83-4 CAPLUS
CN 2H-Indol-2-one, 5,7-difluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-84-5 CAPLUS
CN 2H-Indol-2-one, 6-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-85-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6-methoxy-7-methyl- (CA INDEX NAME)



RN 867154-86-7 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-87-8 CAPLUS
CN 2H-Indol-2-one, 6-chloro-7-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-88-9 CAPLUS
CN 1H-Indole-7-carbonitrile, 2,3-dihydro-3,3-bis(4-hydroxyphenyl)-2-oxo- (CA INDEX NAME)



RN 867154-89-0 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-90-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)-5-methoxy-7-methyl- (CA INDEX NAME)



RN 867154-91-4 CAPLUS
CN 2H-Indol-2-one, 6-fluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 867154-93-6 CAPLUS
CN Pentanoic acid, 5-[[2,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl-2-oxo-1H-indol-6-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 867154-94-7 CAPLUS
CN Pentanoic acid, 5-[[2,3-dihydro-3,3-bis(4-hydroxyphenyl)-7-methyl-2-oxo-1H-indol-6-yl]oxy]- (CA INDEX NAME)



RN 867154-95-8 CAPLUS
CN 2H-Indol-2-one, 7-chloro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)-6-methyl- (CA INDEX NAME)



RN 867154-96-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-hydroxy-3,3-bis(4-hydroxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-97-0 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-3-(4-hydroxyphenyl)-7-methyl-3-(4-methylphenyl)- (CA INDEX NAME)



RN 867154-98-1 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)-7-methyl- (CA INDEX NAME)



RN 867154-99-2 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxyphenyl)-3-(4-methylphenyl)- (CA INDEX NAME)



RN 867155-00-8 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)- (CA INDEX NAME)



RN 867155-01-9 CAPLUS
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-3-(4-hydroxyphenyl)-7-methyl-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 867155-02-0 CAPLUS
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxyphenyl)-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L9 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:962211 CAPLUS
DOCUMENT NUMBER: 143:266816
TITLE: Preparation of 3-3-di-substituted oxindoles as inhibitors of translation initiation
INVENTOR(S): Halperin, Jose A.; Natarajan, Amarnath; Aktas, Huseyin; Fan, Yun-Hua; Chen, Han
PATENT ASSIGNEE(S): President and Fellows of Harvard College, USA
SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080335	A1	20050901	WO 2005-US4373	20050211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005214338	A1	20050901	AU 2005-214338	20050211
CA 2555812	A1	20050901	CA 2005-2555812	20050211
EP 1718611	A1	20061108	EP 2005-722960	20050211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007522234	T	20070809	JP 2006-553263	20050211
US 20070099976	A1	20070503	US 2006-463421	20060809
US 20090299058	A1	20091203	US 2009-368588	20090210

PRIORITY APPLN. INFO.:
US 2004-544384P P 20040213
WO 2005-US4373 W 20050211
US 2006-463421 A3 20060809

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:266816; MARPAT 143:266816
GI



I



II

AB A compds. I [A = carbocyclic aromatic, heterocyclic and heteroarom. ring; R1 = haloalkyl, (un)substituted (alkyl)aryl, halogen, CN, CO2H, alkenyl, alkynyl, alkoxy and cycloalkyl; R2, R3 and R4 = independently (un)substituted aryl, heterocyclic, heteroarom., Ar-NHSO2Ar and Ar-NHCO-Ar; X and Y = independently (un)substituted N, O, S and C; n = 0-4] were prepared as inhibitors of translation initiation for treating of

cellular proliferative disorder in a human and non-human mammals. Thus, compound II was prepared by condensation of 3-bromoaniline with hydroxylamine hydrochloride and chloral hydrate, following by cyclization and phenylation, and showed pos. calcium release from intracellular stores and IC50 = 8 for lung cancer cell growth inhibition.

IT 125-13-3P 1922-79-8P 20367-87-7P
36137-10-7P 36137-11-8P 41007-58-3P
51180-86-0P 51180-87-1P 63483-15-8P
67241-13-8P 210549-74-9P 685890-62-4P
685890-64-6P 685890-67-9P 685890-69-1P
685890-72-6P 685890-79-3P 685890-82-8P
685890-84-0P 685890-86-2P 685890-88-4P
685890-90-8P 685890-91-9P 685890-93-1P
685890-94-2P 685890-95-3P 685890-96-4P
783324-17-4P 783324-18-5P 783324-19-6P
783324-20-9P 863778-85-2P 863778-90-9P
863778-92-1P 863778-97-6P 863779-00-4P
863779-06-0P 863779-08-2P 863779-09-3P
863779-10-6P 863779-11-7P 863779-12-8P
863779-13-9P 863779-15-1P 863779-16-2P
863779-17-3P 863779-18-4P 863779-19-5P
863779-20-8P 863779-21-9P 863779-22-0P
863779-23-1P 863779-24-2P 863779-25-3P
863779-26-4P 863779-27-5P 863779-28-6P
863779-29-7P 863779-30-0P 863779-31-1P
863779-32-2P 863779-33-3P 863779-34-4P
863779-35-5P 863779-36-6P 863779-37-7P
863779-38-8P 863779-39-9P 863779-40-2P
863779-41-3P 863779-42-4P 863779-43-5P
863779-44-6P 863779-45-7P 863779-46-8P
863779-47-9P 863779-48-0P 863779-49-1P
863779-50-4P 863779-51-5P 863779-52-6P
863779-53-7P 863779-54-8P 863779-55-9P
863779-56-0P 863779-57-1P 863779-58-2P
863779-59-3P 863779-60-6P 863779-61-7P
863779-62-8P 863779-63-9P 863779-64-0P
863779-65-1P 863779-66-2P 863779-67-3P
863779-68-4P 863779-69-5P 863779-70-8P
863779-71-9P 863779-72-0P 863779-73-1P
863779-74-2P 863779-75-3P 863779-76-4P
863779-77-5P 863779-78-6P 863779-79-7P
863779-80-0P 863779-81-1P 863779-82-2P
863779-83-3P 863779-85-5P 863779-87-7P
863779-88-8P 863779-89-9P 863779-90-2P
863779-91-3P 863779-92-4P 863779-93-5P
863779-94-6P 863779-95-7P 863779-96-8P
863780-00-1P 863780-01-2P 863780-02-3P
863780-03-4P 863780-04-5P 863780-05-6P
863780-27-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted oxindoles as inhibitors of translation initiation)

RN 125-13-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 1922-79-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 20367-87-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3,3-diphenyl- (CA INDEX NAME)



RN 36137-10-7 CAPLUS
CN 1H-Indole-7-carboxylic acid, 2,3-dihydro-2-oxo-3,3-diphenyl-, methyl ester (CA INDEX NAME)



RN 36137-11-8 CAPLUS
CN 1H-Indole-7-carboxylic acid, 2,3-dihydro-2-oxo-3,3-diphenyl- (CA INDEX NAME)



RN 41007-58-3 CAPLUS
CN 2H-Indol-2-one, 6-bromo-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 51180-86-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-methoxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 51180-87-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-methoxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 63483-15-8 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 67241-13-8 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 210549-74-9 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-62-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-iodo-3,3-diphenyl- (CA INDEX NAME)



RN 685890-64-6 CAPLUS
CN 2H-Indol-2-one, 5-ethyl-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-67-9 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-2-oxo-3,3-diphenyl- (CA INDEX NAME)



RN 685890-69-1 CAPLUS
CN 2H-Indol-2-one, 4-bromo-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-72-6 CAPLUS
CN 2H-Indol-2-one, 7-bromo-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-79-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(3-methoxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 685890-82-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-hydroxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 685890-84-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-hydroxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 685890-86-2 CAPLUS
CN 2H-Indol-2-one, 3-[3-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 685890-88-4 CAPLUS
CN 2H-Indol-2-one, 3-[4-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 685890-90-8 CAPLUS
CN 2H-Indol-2-one, 3-[4-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 685890-91-9 CAPLUS
CN 2H-Indol-2-one, 3-[4-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 685890-93-1 CAPLUS
CN 2H-Indol-2-one, 3-[4-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 685890-94-2 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 685890-95-3 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-5-iodo-3-phenyl- (CA INDEX NAME)



RN 685890-96-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-3-phenyl- (CA INDEX NAME)



RN 783324-17-4 CAPLUS
CN Benzenesulfonamide, N-[5-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-2-

hydroxy-4-methylphenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 783324-18-5 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 783324-19-6 CAPLUS
CN [1,1'-Biphenyl]-4-sulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]- (CA INDEX NAME)



RN 783324-20-9 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-4-phenoxy- (CA INDEX NAME)



RN 863778-85-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-diphenyl-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 863778-90-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-7-iodo-3,3-diphenyl- (CA INDEX NAME)



RN 863778-92-1 CAPLUS
CN 2H-Indol-2-one, 7-ethyl-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 863778-97-6 CAPLUS
CN 2H-Indol-2-one, 4-ethyl-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 863779-00-4 CAPLUS
CN 2H-Indol-2-one, 6-ethyl-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 863779-06-0 CAPLUS
CN 1H-Indole-7-carboxylic acid, 4-chloro-2,3-dihydro-2-oxo-3,3-diphenyl-, methyl ester (CA INDEX NAME)



RN 863779-08-2 CAPLUS
CN 1H-Indole-7-carboxamide, N-[2-(4-aminophenyl)ethyl]-4-chloro-2,3-dihydro-2-oxo-3,3-diphenyl- (CA INDEX NAME)



RN 863779-09-3 CAPLUS
CN 1H-Indole-7-carboxylic acid, 4-chloro-2,3-dihydro-2-oxo-3,3-diphenyl- (CA INDEX NAME)



RN 863779-10-6 CAPLUS
CN 2H-Indol-2-one, 4-chloro-1,3-dihydro-7-(hydroxymethyl)-3,3-diphenyl- (CA INDEX NAME)



RN 863779-11-7 CAPLUS
CN 2H-Indol-2-one, 4-chloro-1,3-dihydro-7-(1H-imidazol-1-ylmethyl)-3,3-diphenyl- (CA INDEX NAME)



RN 863779-12-8 CAPLUS
CN Tyrosine, 3-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-, methyl ester (CA INDEX NAME)



RN 863779-13-9 CAPLUS
CN Tyrosine, 3-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, methyl ester (CA INDEX NAME)



RN 863779-15-1 CAPLUS

CN 2H-Indol-2-one, 3-(2,5-dihydroxyphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-16-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[2-hydroxy-5-(4-penten-1-yloxy)phenyl]-3-phenyl- (CA INDEX NAME)



RN 863779-17-3 CAPLUS
CN 2H-Indol-2-one, 3-[5-(4-bromobutoxy)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-18-4 CAPLUS
CN 2H-Indol-2-one, 3-[5-[4-(dimethylamino)butoxy]-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-19-5 CAPLUS
CN 2H-Indol-2-one, 3-[5-(4-azidobutoxy)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-20-8 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[3-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-hydroxyphenyl]methyl]- (CA INDEX NAME)



RN 863779-21-9 CAPLUS
CN 2H-Indol-2-one, 3-[5-(4-aminobutoxy)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-22-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-hydroxy-5-methylphenyl)-3-phenyl- (CA INDEX NAME)



RN 863779-23-1 CAPLUS
CN 2H-Indol-2-one, 3-(5-heptyl-2-hydroxyphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-24-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-hydroxy-5-nonylphenyl)-3-phenyl- (CA INDEX NAME)



RN 863779-25-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[2-hydroxy-5-(2-methylpropyl)phenyl]-3-phenyl- (CA INDEX NAME)



RN 863779-26-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[2-hydroxy-5-(1-methylethyl)phenyl]-3-phenyl- (CA INDEX NAME)



RN 863779-27-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-hydroxy-5-propylphenyl)-3-phenyl- (CA INDEX NAME)



RN 863779-28-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-hydroxy-5-octylphenyl)-3-phenyl- (CA INDEX NAME)



RN 863779-29-7 CAPLUS
CN 2H-Indol-2-one, 3-(5-ethyl-2-hydroxyphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-30-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-hydroxy-5-pentylphenyl)-3-phenyl- (CA INDEX NAME)



RN 863779-31-1 CAPLUS
CN 2H-Indol-2-one, 3-(5-butyl-2-hydroxyphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-32-2 CAPLUS
CN 2H-Indol-2-one, 3-(5-hexyl-2-hydroxyphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-33-3 CAPLUS
CN 2H-Indol-2-one, 3-(5-cyclopentyl-2-hydroxyphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-34-4 CAPLUS
CN 2H-Indol-2-one, 3-(5-cyclohexyl-2-hydroxyphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-35-5 CAPLUS
CN Benzenesulfonamide, N-[4-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-3-hydroxyphenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 863779-36-6 CAPLUS
CN Benzenesulfonamide, N-[3-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-hydroxyphenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 863779-37-7 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-3-(4-fluorophenyl)-1,3-dihydro- (CA INDEX NAME)



RN 863779-38-8 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-[4-(4-penten-1-yloxy)phenyl]- (CA INDEX NAME)



RN 863779-39-9 CAPLUS
CN 2H-Indol-2-one, 3-(3-chlorophenyl)-3-[5-(1,1-dimethylethyl)-2-

hydroxyphenyl]-1,3-dihydro- (CA INDEX NAME)



RN 863779-40-2 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-3-(3-fluorophenyl)-1,3-dihydro- (CA INDEX NAME)



RN 863779-41-3 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-(3-methylphenyl)- (CA INDEX NAME)



RN 863779-42-4 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-(2-methylphenyl)- (CA INDEX NAME)



RN 863779-43-5 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 863779-44-6 CAPLUS
CN Sulfuric acid, 2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-(1,1-dimethylethyl)phenyl 1,7,7-trimethylbicyclo[2.2.1]hept-2-yl ester (CA INDEX NAME)



RN 863779-45-7 CAPLUS
CN Octanedioic acid, 1-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-(1,1-dimethylethyl)phenyl] ester (CA INDEX NAME)



RN 863779-46-8 CAPLUS
CN Pentanoic acid, 5-(hydroxyamino)-5-oxo-, 2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-(1,1-dimethylethyl)phenyl ester (CA INDEX NAME)



RN 863779-47-9 CAPLUS
CN Carbamic acid, [2-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-(1,1-dimethylethyl)phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 863779-48-0 CAPLUS
CN Pentanedioic acid, 1-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-(1,1-dimethylethyl)phenyl] ester (CA INDEX NAME)



RN 863779-49-1 CAPLUS
CN Acetic acid, 2-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-(1,1-dimethylethyl)phenoxy]- (CA INDEX NAME)



RN 863779-50-4 CAPLUS
CN Acetic acid, 2-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-4-(1,1-dimethylethyl)phenoxy]-, methyl ester (CA INDEX NAME)



RN 863779-51-5 CAPLUS
CN 2H-Indol-2-one, 7-bromo-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-52-6 CAPLUS
CN 2H-Indol-2-one, 4-chloro-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-53-7 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-54-8 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-5-nitro-3-phenyl- (CA INDEX NAME)



RN 863779-55-9 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-5-methoxy-3-phenyl- (CA INDEX NAME)



RN 863779-56-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-57-1 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl-7-(trifluoromethyl)- (CA INDEX NAME)



RN 863779-58-2 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-59-3 CAPLUS
CN 2H-Indol-2-one, 4-bromo-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-60-6 CAPLUS
CN 2H-Indol-2-one, 6-bromo-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-61-7 CAPLUS
CN 1-Naphthalenesulfonamide, N-[3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-2,3-dihydro-2-oxo-3-phenyl-1H-indol-5-yl]- (CA INDEX NAME)



RN 863779-62-8 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-7-methoxy-3-phenyl- (CA INDEX NAME)



RN 863779-63-9 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-7-iodo-3-phenyl- (CA INDEX NAME)



RN 863779-64-0 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-5-ethyl-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-65-1 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-7-ethyl-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-66-2 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-4-ethyl-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-67-3 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-6-ethyl-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-68-4 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-5-fluoro-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-69-5 CAPLUS
CN 2H-Indol-2-one, 5-azido-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-70-8 CAPLUS
CN 1H-Indole-7-carboxylic acid, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-2,3-dihydro-2-oxo-3-phenyl- (CA INDEX NAME)



RN 863779-71-9 CAPLUS
CN 1H-Indole-7-carboxylic acid, 4-chloro-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-2,3-dihydro-2-oxo-3-phenyl- (CA INDEX NAME)



RN 863779-72-0 CAPLUS
CN 2H-Indol-2-one, 6-chloro-3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-73-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(2-hydroxy-4-methoxyphenyl)- (CA INDEX NAME)



RN 863779-74-2 CAPLUS
CN 2H-Indol-2-one, 3,3-bis[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro- (CA INDEX NAME)





RN 863779-75-3 CAPLUS
CN 2H-Indol-2-one, 3-[3-[4-(dimethylamino)butoxy]-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-76-4 CAPLUS
CN 2H-Indol-2-one, 3-[3-(4-azidobutoxy)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-77-5 CAPLUS
CN 2H-Indol-2-one, 3-(4-chlorophenyl)-1,3-dihydro-3-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 863779-78-6 CAPLUS
CN 2H-Indol-2-one, 3-[3-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 863779-79-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-hydroxyphenyl)-3-(4-phenoxyphenyl)- (CA

INDEX NAME)



RN 863779-80-0 CAPLUS
CN 2H-Indol-2-one, 3-[1,1'-biphenyl]-4-yl-1,3-dihydro-3-(4-hydroxyphenyl)-
(CA INDEX NAME)



RN 863779-81-1 CAPLUS
CN 2H-Indol-2-one, 3-[4-(dimethylamino)phenyl]-1,3-dihydro-3-(4-
hydroxyphenyl)- (CA INDEX NAME)



RN 863779-82-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-phenyl-3-(4-propylphenyl)- (CA INDEX NAME)



RN 863779-83-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[4-(2-methylpropyl)phenyl]-3-phenyl- (CA INDEX NAME)



RN 863779-85-5 CAPLUS
CN 2H-Indol-2-one, 3-(4-butylphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-87-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[4-(2-hydroxyethoxy)phenyl]-3-phenyl- (CA INDEX NAME)



RN 863779-88-8 CAPLUS
CN Benzeneacetic acid, 2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-methoxy- (CA INDEX NAME)



RN 863779-89-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[4-hydroxy-3-(trifluoromethyl)phenyl]-3-phenyl- (CA INDEX NAME)



RN 863779-90-2 CAPLUS
CN 2H-Indol-2-one, 3-(3-fluoro-4-hydroxyphenyl)-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 863779-91-3 CAPLUS
CN 1H-Indole-7-carboxylic acid, 3-[2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-hydroxy-5-methylphenyl]-2,3-dihydro-2-oxo-3-phenyl- (CA INDEX NAME)



RN 863779-92-4 CAPLUS
CN Carbamic acid, [2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



RN 863779-93-5 CAPLUS
CN Benzenemethanesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]- (CA INDEX NAME)



RN 863779-94-6 CAPLUS
CN 1H-Indole-7-carboxylic acid, 2,3-dihydro-3-[4-hydroxy-5-methyl-2-[(methylsulfonyl)amino]phenyl]-2-oxo-3-phenyl- (CA INDEX NAME)



RN 863779-95-7 CAPLUS
CN Methanesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]- (CA INDEX NAME)



RN 863779-96-8 CAPLUS
CN 1H-Indole-7-carboxylic acid, 3-[2-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-4-hydroxy-5-methylphenyl]-2,3-dihydro-2-oxo-3-phenyl- (CA INDEX NAME)



RN 863780-00-1 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-4-nitro- (CA INDEX NAME)



RN 863780-01-2 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-4-methoxy- (CA INDEX NAME)



RN 863780-02-3 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]- (CA INDEX NAME)



RN 863780-03-4 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-4-iodo- (CA INDEX NAME)



RN 863780-04-5 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxyphenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 863780-05-6 CAPLUS
CN Acetamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]- (CA INDEX NAME)



RN 863780-27-2 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-(2,3,4,5,6-pentafluorophenyl)- (CA INDEX NAME)



IT 863779-97-9P 863779-98-0P 863779-99-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted oxindoles as inhibitors of translation initiation)
RN 863779-97-9 CAPLUS
CN Benzamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 863779-98-0 CAPLUS
CN Acetamide, N-[4-[[[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]amino]sulfonyl]phenyl]- (CA INDEX NAME)



RN 863779-99-1 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:725576 CAPLUS
DOCUMENT NUMBER: 141:374412
TITLE: Novel Arylsulfoanilide-Oxindole Hybrid as an Anticancer Agent That Inhibits Translation Initiation

AUTHOR(S): Natarajan, Amarnath; Guo, Yuhong; Harbinski, Frederick; Fan, Yun-Hua; Chen, Han; Luus, Lia; Diercks, Jana; Aktas, Huseyin; Chorev, Michael; Halperin, Jose A.
CORPORATE SOURCE: Laboratory for Translational Research, Harvard Medical School, Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(21), 4979-4982
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:374412
AB Structure-activity relationship studies of substituted arylsulfoanilides as antiproliferatives, which are mediated by the partial depletion of intracellular Ca2+ stores, resulted in the identification of compds. with micromolar activity against lung cancer cells in a growth inhibition assay. Incorporating the substitution pattern of the best arylsulfoanilides onto the 3-phenyloxindole scaffold resulted in a potent arylsulfoanilide-oxindole hybrid, 27. Compound 27 inhibits cancer cell growth by partial depletion of intracellular Ca2+ stores and phosphorylation of eIF2α.
IT 783324-17-4 783324-18-5 783324-19-6
783324-20-9
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation)
RN 783324-17-4 CAPLUS
CN Benzenesulfonamide, N-[5-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-2-hydroxy-4-methylphenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 783324-18-5 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 783324-19-6 CAPLUS
CN [1,1'-Biphenyl]-4-sulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]- (CA INDEX NAME)



RN 783324-20-9 CAPLUS
CN Benzenesulfonamide, N-[2-(2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl)-5-hydroxy-4-methylphenyl]-4-phenoxy- (CA INDEX NAME)



IT 1922-79-8 685890-94-2
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation)
RN 1922-79-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-94-2 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:189011 CAPLUS
DOCUMENT NUMBER: 140:391175
TITLE: 3,3-Diaryl-1,3-dihydroindol-2-ones as Antiproliferatives Mediated by Translation Initiation Inhibition
AUTHOR(S): Natarajan, Amarnath; Fan, Yun-Hua; Chen, Han; Guo, Yuhong; Iyasere, Julia; Harbinski, Frederick; Christ, William J.; Aktas, Huseyin; Halperin, Jose A.
CORPORATE SOURCE: Laboratory for Translational Research, Harvard Medical School, Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(8), 1882-1885
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:391175

AB A series of substituted 3,3-diphenyl-1,3-dihydroindol-2-ones was synthesized from the corresponding isatins. The compds. were studied for cell growth inhibition mediated by partial depletion of intracellular Ca2+ stores that leads to phosphorylation of eIF2α. 3,3-Diphenyloxindole showed mechanism-specific antiproliferative activity that was comparable to known translation initiation inhibitors such as clotrimazole or troglitazone. SAR studies identified 3-(5-tert.-butyl-2-hydroxyphenyl)-3-phenyloxindole as a lead compound for Ca2+-depletion-mediated inhibition of translation initiation.

IT 1922-79-8P 20367-87-7P 41007-58-3P
51180-86-0P 51180-87-1P 63483-15-8P
67241-13-8P 210549-74-9P 685890-62-4P
685890-64-6P 685890-67-9P 685890-69-1P
685890-72-6P 685890-79-3P 685890-82-8P
685890-84-0P 685890-86-2P 685890-88-4P
685890-90-8P 685890-91-9P 685890-93-1P
685890-94-2P 685890-95-3P 685890-96-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 3,3-diaryl-1,3-dihydroindol-2-ones as antiproliferatives mediated by translation initiation inhibition)

RN 1922-79-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 20367-87-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3,3-diphenyl- (CA INDEX NAME)



RN 41007-58-3 CAPLUS
CN 2H-Indol-2-one, 6-bromo-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 51180-86-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-methoxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 51180-87-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-methoxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 63483-15-8 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 67241-13-8 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 210549-74-9 CAPLUS
CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-62-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-iodo-3,3-diphenyl- (CA INDEX NAME)



RN 685890-64-6 CAPLUS
CN 2H-Indol-2-one, 5-ethyl-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-67-9 CAPLUS
CN 1H-Indole-5-sulfonic acid, 2,3-dihydro-2-oxo-3,3-diphenyl- (CA INDEX NAME)



RN 685890-69-1 CAPLUS
CN 2H-Indol-2-one, 4-bromo-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-72-6 CAPLUS
CN 2H-Indol-2-one, 7-bromo-1,3-dihydro-3,3-diphenyl- (CA INDEX NAME)



RN 685890-79-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(3-methoxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 685890-82-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(2-hydroxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 685890-84-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-hydroxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 685890-86-2 CAPLUS
CN 2H-Indol-2-one, 3-[3-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 685890-88-4 CAPLUS
CN 2H-Indol-2-one, 3-[4-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 685890-90-8 CAPLUS
CN 2H-Indol-2-one, 3-[4-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)



RN 685890-91-9 CAPLUS
CN 2H-Indol-2-one, 3-[4-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 685890-93-1 CAPLUS
CN 2H-Indol-2-one, 3-[4-(1,1-dimethylethyl)phenyl]-1,3-dihydro-3-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 685890-94-2 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)



RN 685890-95-3 CAPLUS
CN 2H-Indol-2-one, 3-[5-(1,1-dimethylethyl)-2-hydroxyphenyl]-1,3-dihydro-5-iodo-3-phenyl- (CA INDEX NAME)



RN 685890-96-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-3-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:757676 CAPLUS
DOCUMENT NUMBER: 139:276813
TITLE: Preparation of dihydroindol-2-ones as steroid hormone nuclear receptor modulators for treatment of congestive heart failure and other conditions
INVENTOR(S): Grese, Timothy Alan; Jadhav, Prabhakar Kondaji; Neel, David Andrew; Steinberg, Mitchell Irvin; Lander, Peter Ambrose
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078394	A1	20030925	WO 2003-US6152	20030311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478172	A1	20030925	CA 2003-2478172	20030311
AU 2003230581	A1	20030929	AU 2003-230581	20030311
EP 1487792	A1	20041222	EP 2003-723665	20030311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508893	T	20060316	JP 2003-576400	20030311
US 20050054712	A1	20050310	US 2004-506175	20040831
US 7250442	B2	20070731		

PRIORITY APPLN. INFO.:	US 2002-365212P	P	20020315
	WO 2003-US6152	W	20030311

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 139:276813

GI



AB Title compds. I [wherein R1 = (halo)alkyl, cycloalkoxy, (alkyl)cycloalkyl, alkyl(cyclo)alkoxy, alkenyl, alkynyl, CH2CN, CH2COR7, or (un)substituted (alkyl)aryl or (alkyl)heterocyclyl; R2 = (halo)alkyl, hydroxyalkyl, (alkyl)cycloalkyl, alkylalkoxy, alkenyl, or (un)substituted phenyl(alkyl); R3 = (un)substituted Ph; R4 and R5 = independently H, halo, OH, (cyclo)alkyl, alkoxy, CF3, OCF3, OCHF2, CF2CF3, CN, NO2, NH2, NH-alkylamine, or N,N-dialkylamine; R7 = alkyl, cycloalkyl(amino), alkoxy, or (un)substituted aryl or heterocyclyl; and pharmaceutically acceptable salts thereof] were prepared as steroid hormone nuclear receptor modulators. For example, alkylation of 3,3-bis[4-(tert-butyldimethylsilanyloxy)-3,5-dimethylphenyl]-1,3-dihydroindol-2-one with 4-methoxybenzyl chloride in the presence of t-BuOK in THF, followed by deprotection using Bu4NF in THF provided II (51%). The latter showed affinity for the human mineralocorticoid receptor (hMR) expressed in Sf9 insect cells with Ki ≤ 500 nM in competition expts. using [3H]-aldosterone as the specific ligand. In a whole cell binding assay using A549 human lung epithelial cells and [3H]-dexamethasone as the ligand, II also demonstrated modulation of glucocorticoid receptor (GR) activity with Ki ≤ 500 nM. Thus, I and their pharmaceutical compns. are useful for treating pathol. disorders susceptible to steroid hormone nuclear receptor modulation, particularly congestive heart failure.

IT 125-13-3P, 3,3-Bis(4-hydroxyphenyl)-1,3-dihydroindol-2-one
20206-19-3P, 3,3-Bis(4-Hydroxy-3,5-dimethylphenyl)-1,3-dihydroindol-2-one 604803-43-2P, 3,3-Bis[4-(tert-butyldimethylsilanyloxy)-3,5-dimethylphenyl]-1,3-dihydroindol-2-one 604803-46-5P, 3,3-Bis[4-(tert-butyldimethylsilanyloxy)phenyl]-1,3-dihydroindol-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indolones as glucocorticoid and mineralocorticoid receptor modulators for treatment of congestive heart failure and other conditions)

RN 125-13-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



RN 20206-19-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxy-3,5-dimethylphenyl)- (CA INDEX NAME)



RN 604803-43-2 CAPLUS
CN 2H-Indol-2-one, 3,3-bis[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3,5-dimethylphenyl]-1,3-dihydro- (CA INDEX NAME)



RN 604803-46-5 CAPLUS
CN 2H-Indol-2-one, 3,3-bis[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-1,3-dihydro- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1993:419929 CAPLUS
DOCUMENT NUMBER: 119:19929
ORIGINAL REFERENCE NO.: 119:3513a,3516a
TITLE: Structure-based discovery of inhibitors of thymidylate synthase
AUTHOR(S): Shoichet, Brian K.; Stroud, Robert M.; Santi, Daniel V.; Kuntz, Irwin D.; Perry, Kathy M.
CORPORATE SOURCE: Dep. Pharm. Chem., Univ. California, San Francisco, CA, 94143, USA
SOURCE: Science (Washington, DC, United States) (1993), 259(5100), 1445-50
CODEN: SCIEAS; ISSN: 0036-8075
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A mol. docking computer program (DOCK) was used to screen the Fine Chemical Directory, a database of com. available compds., for mols. that are complementary to thymidylate synthase (TS), a chemotherapeutic target. Besides retrieving the substrate and several known inhibitors, DOCK proposed putative inhibitors previously unknown to bind to the enzyme. Three of these compds. inhibited Lactobacillus casei TS at submillimolar concns. One of these inhibitors, sulisobenzone, crystallized with TS in two configurations that differed from the DOCK-favored geometry: a counterion was bound in the substrate site, which resulted in a 6 to 9 angstrom displacement of the inhibitor. The structure of the complexes suggested another binding region in the active site that could be exploited. This region was probed with mols. sterically similar to sulisobenzone, which led to the identification of a family of phenolphthalein analogs that inhibit TS in the 1 to 30 micromolar range. These inhibitors do not resemble the substrates of the enzyme. A crystal structure of phenolphthalein with TS shows that it binds in the target site in a configuration that resembles the one suggested by DOCK.
IT 125-13-3, 3,3-Bis(4-hydroxyphenyl)oxindole
RL: BIOL (Biological study)
(as thymidylate synthase inhibitor, structure in relation to)
RN 125-13-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 164 THERE ARE 164 CAPLUS RECORDS THAT CITE THIS RECORD (164 CITINGS)

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	83.96	280.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.20	-10.20

FILE 'STNGUIDE' ENTERED AT 11:00:19 ON 08 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 2, 2010 (20100402/UP).

=> d his

(FILE 'HOME' ENTERED AT 10:52:16 ON 08 APR 2010)

FILE 'REGISTRY' ENTERED AT 10:52:33 ON 08 APR 2010
L1 STRUCTURE UPLOADED
L2 42 S L1 SSS
L3 STRUCTURE UPLOADED
L4 40 S L3 SSS
L5 592 S L3 FULL

FILE 'CAPLUS' ENTERED AT 10:54:34 ON 08 APR 2010
L6 394 S L5
L7 996285 S (CANCER OR TUMOR OR NEOPLASM OR TUMOUR)
L8 12 S L6 AND L7
L9 12 DUP REM L8 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 11:00:19 ON 08 APR 2010

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.07	280.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.20

STN INTERNATIONAL LOGOFF AT 11:00:53 ON 08 APR 2010